A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

• Status: Completed
• Trial end date: 2017-08-02
• Target enrollment: 0
• Participant gender: All

Summary

Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Spyryx Biosciences, Inc.
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Confirmed diagnosis of CF

• FEV1 ≥ 40% predicted normal

• Stable CF lung disease

• Non-pregnant, non-lactating females

Exclusion Criteria:

• Significant unstable co-morbidities within 28 days of screening as judged by the Investigator.

• Has received an investigational drug within the past 30 days